Article

Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property.

Laboratory of Neurophysiology, Department of Physiology, University of Concepción, Concepción, Chile.
PLoS ONE (impact factor: 4.09). 01/2010; 5(7):e11820. DOI:10.1371/journal.pone.0011820 pp.e11820
Source: PubMed

ABSTRACT The mechanisms that induce Alzheimer's disease (AD) are largely unknown thereby deterring the development of disease-modifying therapies. One working hypothesis of AD is that Abeta excess disrupts membranes causing pore formation leading to alterations in ionic homeostasis. However, it is largely unknown if this also occurs in native brain neuronal membranes. Here we show that similar to other pore forming toxins, Abeta induces perforation of neuronal membranes causing an increase in membrane conductance, intracellular calcium and ethidium bromide influx. These data reveal that the target of Abeta is not another membrane protein, but that Abeta itself is the cellular target thereby explaining the failure of current therapies to interfere with the course of AD. We propose that this novel effect of Abeta could be useful for the discovery of anti AD drugs capable of blocking these "Abeta perforates". In addition, we demonstrate that peptides that block Abeta neurotoxicity also slow or prevent the membrane-perforating action of Abeta.

0 0
 · 
0 Bookmarks
 · 
52 Views
  • Source
    Article: Alzheimer's disease is a synaptic failure.
    [show abstract] [hide abstract]
    ABSTRACT: In its earliest clinical phase, Alzheimer's disease characteristically produces a remarkably pure impairment of memory. Mounting evidence suggests that this syndrome begins with subtle alterations of hippocampal synaptic efficacy prior to frank neuronal degeneration, and that the synaptic dysfunction is caused by diffusible oligomeric assemblies of the amyloid beta protein.
    Science 11/2002; 298(5594):789-91. · 31.20 Impact Factor
  • Source
    Article: Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
    [show abstract] [hide abstract]
    ABSTRACT: Accumulation of beta-amyloid (Abeta) peptide and hyperphosphorylation of tau in the brain are pathological hallmarks of Alzheimer's disease (AD). Agents altering these pathological events might modify clinical disease progression. NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) is an octapeptide that has shown neuroprotective effects in various in vitro and in vivo neurodegenerative models. Previous studies showed that NAP protected against Abeta-induced neurotoxicity, inhibited Abeta aggregation, and, by binding to tubulin, prevented disruption of microtubules. In this study, we investigated the effect of NAP on Abeta and tau pathology using a transgenic mouse model that recapitulates both aspects of AD. We administered NAP intranasally (0.5 microg/mouse per day, daily from Monday through Friday) for 3 mo, starting from 9 mo of age, which is a prepathological stage in these mice. NAP treatment significantly lowered levels of Abeta 1-40 and 1-42 in brain. In addition, NAP significantly reduced levels of hyperphosphorylated tau. Of particular interest, hyperphosphorylation at the threonine 231 site was reduced; phosphorylation at this site influences microtubule binding. Our results indicate that NAP treatment of transgenic mice initiated at an early stage reduced both Abeta and tau pathology, suggesting that NAP might be a potential therapeutic agent for AD.
    Journal of Molecular Neuroscience 02/2007; 31(2):165-70. · 2.50 Impact Factor
  • Article: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.
    [show abstract] [hide abstract]
    ABSTRACT: The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
    Nature Reviews Molecular Cell Biology 03/2007; 8(2):101-12. · 39.12 Impact Factor

Full-text (2 Sources)

View
4 Downloads
Available from
5 Feb 2013

Keywords

Abeta
 
Abeta excess disrupts membranes
 
Abeta induces perforation
 
Abeta perforates"
 
alterations
 
block Abeta neurotoxicity
 
disease-modifying therapies
 
induce Alzheimer's disease
 
intracellular calcium
 
membrane protein
 
membrane-perforating action
 
native brain neuronal membranes
 
neuronal membranes
 
toxins
 
working hypothesis